Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

323 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial.
Ikeda M, Kudo M, Aikata H, Nagamatsu H, Ishii H, Yokosuka O, Torimura T, Morimoto M, Ikeda K, Kumada H, Sato T, Kawai I, Yamashita T, Horio H, Okusaka T; Miriplatin TACE Study Group. Ikeda M, et al. Among authors: torimura t. J Gastroenterol. 2018 Feb;53(2):281-290. doi: 10.1007/s00535-017-1374-6. Epub 2017 Aug 1. J Gastroenterol. 2018. PMID: 28766016 Free PMC article. Clinical Trial.
Sclerosing hepatocellular carcinoma with hypercalcemia--a case report.
Yamashita F, Iwao T, Torimura T, Tanaka M, Hirai K, Abe M, Toyonaga A, Sugihara S, Kojiro M, Tanikawa K. Yamashita F, et al. Among authors: torimura t. Kurume Med J. 1992;39(2):113-6. doi: 10.2739/kurumemedj.39.113. Kurume Med J. 1992. PMID: 1328759 Free article.
Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy.
Nagamatsu H, Itano S, Nagaoka S, Akiyoshi J, Matsugaki S, Kurogi J, Tajiri N, Yamasaki S, Koga H, Torimura T, Kumashiro R, Sata M. Nagamatsu H, et al. Among authors: torimura t. Am J Gastroenterol. 2004 Dec;99(12):2369-75. doi: 10.1111/j.1572-0241.2004.40069.x. Am J Gastroenterol. 2004. PMID: 15571585
Serum C-reactive protein levels predict survival in hepatocellular carcinoma.
Nagaoka S, Yoshida T, Akiyoshi J, Akiba J, Torimura T, Adachi H, Kurogi J, Tajiri N, Inoue K, Niizeki T, Koga H, Imaizumi T, Kojiro M, Sata M. Nagaoka S, et al. Among authors: torimura t. Liver Int. 2007 Oct;27(8):1091-7. doi: 10.1111/j.1478-3231.2007.01550.x. Liver Int. 2007. PMID: 17845537
Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy.
Niizeki T, Sumie S, Torimura T, Kurogi J, Kuromatsu R, Iwamoto H, Aino H, Nakano M, Kawaguchi A, Kakuma T, Sata M. Niizeki T, et al. Among authors: torimura t. J Gastroenterol. 2012 Jun;47(6):686-95. doi: 10.1007/s00535-012-0555-6. Epub 2012 Mar 1. J Gastroenterol. 2012. PMID: 22382631 Clinical Trial.
Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma.
Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Sakata K, Matsugaki S, Kajiwara M, Fukuizumi K, Tajiri N, Matsukuma N, Sakai T, Ono N, Yano Y, Koga H, Kurogi J, Takata A, Sumie S, Satani M, Yamada S, Niizeki T, Aino H, Iwamoto H, Torimura T, Sata M. Nakano M, et al. Among authors: torimura t. Oncology. 2013;84(2):108-14. doi: 10.1159/000342650. Epub 2012 Nov 9. Oncology. 2013. PMID: 23147476
323 results